Review of peptide-drug conjugates as cancer therapeutics covers design principles, targeting mechanisms, clinical candidates, and advantages over antibody-drug conjugates.
Key findingReview of peptide-drug conjugates as cancer therapeutics covers design principles, targeting mechani
What the researchers found
Review of peptide-drug conjugates as cancer therapeutics covers design principles, targeting mechanisms, clinical candidates, and advantages over antibody-drug conjugates.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Only one PDC (Lutathera) currently FDA-approved. Pepaxto was approved then withdrawn from market.
How the study worked
In publication.
Who was studied
Cancer patients (various tumor types targeted by PDC candidates)
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Peptide-Drug Conjugates: A New Hope for Cancer.
Journal of peptide science : an official publication of the European Peptide Society, 31(8), e70040
Citation
Armstrong, Amy; Coburn, Fleur; Nsereko, Yanyamba; Al Musaimi, Othman. (2025). Peptide-Drug Conjugates: A New Hope for Cancer.. Journal of peptide science : an official publication of the European Peptide Society, 31(8), e70040. https://doi.org/10.1002/psc.70040